EL7.AI
StocksMedium•31 March 2026•
1 min read

Telomir Pharmaceuticals Files FDA IND Application for Breast Cancer Therapy

Key Facts

1Telomir Pharmaceuticals (NASDAQ: TELO) submitted an Investigational New Drug (IND) application to the FDA for its lead candidate, Telomir-1.
2The drug candidate targets advanced and metastatic Triple-Negative Breast Cancer (TNBC).
3Telomir-1 is a metal-modulating epigenetic therapy targeting iron-dependent pathways in cancer cells.

Telomir Pharmaceuticals (NASDAQ: TELO) has officially submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead candidate, Telomir-1. The therapeutic candidate is specifically designed to target advanced and metastatic Triple-Negative Breast Cancer (TNBC), a challenging form of the disease. Telomir-1 utilizes a metal-modulating epigenetic approach that targets iron-dependent pathways within cancer cells to inhibit their progression. This submission follows successful preclinical efficacy studies which demonstrated a favorable safety profile for the small-molecule drug. The filing marks a significant milestone for the company as it transitions from preclinical development to human clinical trials. Regulatory progress of this nature is typically viewed as a key value driver for biotech firms, potentially increasing investor interest in TELO.